共 50 条
Intraperitoneal photodynamic therapy for peritoneal metastasis of epithelial ovarian cancer. Limits and future prospects
被引:8
|作者:
Azais, H.
[1
,2
]
Mordon, S.
[2
]
Collinet, P.
[2
,3
]
机构:
[1] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Serv Chirurg & Cancerol Gynecol & Mammaire, Blvd Hop, F-75013 Paris, France
[2] CHU Lille, INSERM, ONCO THAI Image Assisted Laser Therapy Oncol U118, F-59000 Lille, France
[3] CHRU Lille, Serv Gynecol Medicochirurg, F-59000 Lille, France
来源:
关键词:
Photodynamic therapy;
Ovarian cancer;
Photosensitizer;
Folate receptor;
FOLATE RECEPTOR-ALPHA;
PROTOPORPHYRIN-IX FLUORESCENCE;
PHASE-II TRIAL;
5-AMINOLEVULINIC ACID;
DEBULKING SURGERY;
CYTOREDUCTIVE SURGERY;
PHOTOFRIN UPTAKE;
NORMAL-TISSUES;
TUMOR;
EXPRESSION;
D O I:
10.1016/j.gofs.2017.02.005
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
High peritoneal recurrence rate in advanced epithelial ovarian cancer after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, raises the issue of peritoneal microscopic disease management and requires the development of additional locoregional treatment strategies. Photodynamic therapy is an effective treatment already applied in other medical and surgical indications. After administration of a photosensitizer which accumulates in cancer cells, illumination with a light of adequate wavelength may induce photochemical reaction between photosensitizer and tissue oxygen which lead to reactive oxygen species production and cytotoxic phenomenon. Photodynamic therapy's ability to treat superficial lesions disseminated on large area makes it an excellent candidate to insure destruction of microscopic peritoneal metastases in addition to macroscopic cytoreductive surgery in order to decrease peritoneal recurrence rate. Development of intraperitoneal photodynamic therapy has been limited by its poor tolerance related to the lack of specificity of photosensitizers and the location of the metastases in proximity to adjacent intraperitoneal organs. Our aim is to review clinical data concerning intraperitoneal photodynamic therapy and epithelial ovarian cancer to identify the limits of this strategy and to provide solutions which may be applied to solve these barriers and enable safe and effective treatment. Targeted photosensitizers and innovative illumination solutions are mandatory to continue research in this field and to consider the feasibility of clinical trials. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:249 / 256
页数:8
相关论文